Amplify Weight Loss Drug & Treatment ETF (THNR)
NYSEARCA: THNR · Real-Time Price · USD
24.31
0.00 (0.00%)
Jun 8, 2026, 9:38 AM EDT - Market open
THNR Holdings Information
THNR is an equity ETF with a total of 23 individual holdings. The top holdings are Novo Nordisk stock at 14.42%, Eli Lilly and Company at 14.42%, Amgen at 6.27%, Arrowhead Pharmaceuticals at 5.98%, and Regeneron Pharmaceuticals at 5.62%.
Total Holdings
23
Top 10 Percentage
71.87%
Asset Class
Equity
ETF Category
Health
Assets
4.15M
PE Ratio
17.12
Breakdown by Sector
Top 25 Holdings
| No. | Symbol | Name | % Weight |
|---|---|---|---|
| 1 | NVO | Novo Nordisk A/S | 14.42% |
| 2 | LLY | Eli Lilly and Company | 14.42% |
| 3 | AMGN | Amgen Inc. | 6.27% |
| 4 | ARWR | Arrowhead Pharmaceuticals, Inc. | 5.98% |
| 5 | REGN | Regeneron Pharmaceuticals, Inc. | 5.62% |
| 6 | TYO: 4519 | Chugai Pharmaceutical Co., Ltd. | 5.27% |
| 7 | MRK | Merck & Co., Inc. | 5.14% |
| 8 | SWX: ROP | Roche Holding AG | 5.09% |
| 9 | ABBV | AbbVie Inc. | 4.94% |
| 10 | PFE | Pfizer Inc. | 4.73% |
| 11 | HKG: 1801 | Innovent Biologics, Inc. | 4.72% |
| 12 | LON: AZN | AstraZeneca PLC | 4.68% |
| 13 | HKG: 1093 | CSPC Pharmaceutical Group Limited | 4.03% |
| 14 | TYO: 4507 | Shionogi & Co., Ltd. | 3.98% |
| 15 | SRRK | Scholar Rock Holding Corporation | 2.20% |
| 16 | VKTX | Viking Therapeutics, Inc. | 2.03% |
| 17 | CPH: ZEAL | Zealand Pharma A/S | 1.97% |
| 18 | GPCR | Structure Therapeutics Inc. | 1.64% |
| 19 | KRX: 128940 | Hanmi Pharm. Co., Ltd. | 1.23% |
| 20 | JNGHF | Jiangsu Hengrui Pharmaceuticals Co Ltd Ordinary Shares - Class H | 1.02% |
| 21 | AGPXX | Invesco Short-Term Investments Trust Government & Agency Portfolio Institutional Class | 0.91% |
| 22 | n/a | HONG KONG DOLLAR | 0.00% |
| 23 | n/a | OTHER ASSETS AND LIABILITIES | -0.30% |
As of Jun 4, 2026